Novavax (NASDAQ:NVAX) Downgraded by JPMorgan Chase & Co.
Novavax (NASDAQ:NVAX) Downgraded by JPMorgan Chase & Co.
JPMorgan Chase & Co. downgraded shares of Novavax (NASDAQ:NVAX – Get Rating) from a neutral rating to an underweight rating in a report released on Thursday, The Fly reports. They currently have $27.00 price target on the biopharmaceutical company's stock, down from their prior price target of $132.00.
据The Fly报道,摩根大通在周四发布的一份报告中将诺华公司(纳斯达克代码:NVAX-GET Rating)的股票评级从中性下调至减持。他们目前对这家生物制药公司的股票设定了27美元的目标价,低于之前132.00美元的目标价。
NVAX has been the topic of a number of other reports. Cantor Fitzgerald upped their price target on shares of Novavax from $146.00 to $168.00 in a research note on Wednesday, June 8th. Cowen lowered their price target on shares of Novavax from $150.00 to $110.00 and set an outperform rating on the stock in a research note on Tuesday, August 9th. B. Riley lowered their price objective on shares of Novavax from $181.00 to $171.00 in a research note on Friday, July 22nd. Finally, Cowen lowered their price objective on shares of Novavax to $110.00 in a research note on Monday, August 15th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of Hold and a consensus target price of $128.25.
NVAX一直是其他一些报告的主题。康托·菲茨杰拉德在6月8日星期三的一份研究报告中将诺华公司的目标股价从146.00美元上调至168.00美元。考恩在8月9日周二的一份研究报告中将诺华公司的股票目标价从150.00美元下调至110.00美元,并对该股设定了表现优于大盘的评级。在7月22日星期五的一份研究报告中,B.莱利将诺华的股票目标价从181.00美元下调至171.00美元。最后,考恩在8月15日星期一的一份研究报告中将诺华的股票目标价下调至110.00美元。两名投资分析师对该股的评级为卖出,一名分析师给出了持有评级,五名分析师给出了该公司股票的买入评级。根据MarketBeat的数据,该股目前的共识评级为持有,共识目标价为128.25美元。
Novavax Stock Performance
Novavax股票表现
Shares of NVAX opened at $21.00 on Thursday. The stock has a market capitalization of $1.64 billion, a P/E ratio of -1.08, a P/E/G ratio of 0.10 and a beta of 1.65. The company's fifty day moving average is $41.22 and its two-hundred day moving average is $52.06. Novavax has a 1 year low of $20.46 and a 1 year high of $257.30.
周四,NVAX的股价开盘报21.00美元。该股市值16.4亿美元,市盈率为-1.08,市盈率为0.10,贝塔系数为1.65。该公司的50日移动均线切入位在41.22美元,200日移动均线切入位在52.06美元。诺华的一年低点为20.46美元,一年高位为257.30美元。
Institutional Investors Weigh In On Novavax
机构投资者买入Novavax股票
Several hedge funds have recently modified their holdings of the company. B. Riley Wealth Management Inc. boosted its stake in shares of Novavax by 22.0% during the 2nd quarter. B. Riley Wealth Management Inc. now owns 5,044 shares of the biopharmaceutical company's stock worth $259,000 after purchasing an additional 909 shares during the last quarter. Captrust Financial Advisors boosted its stake in shares of Novavax by 83.3% during the 2nd quarter. Captrust Financial Advisors now owns 6,703 shares of the biopharmaceutical company's stock worth $345,000 after purchasing an additional 3,047 shares during the last quarter. ExodusPoint Capital Management LP boosted its stake in shares of Novavax by 212.8% during the 2nd quarter. ExodusPoint Capital Management LP now owns 21,296 shares of the biopharmaceutical company's stock worth $1,095,000 after purchasing an additional 14,487 shares during the last quarter. Worldquant Millennium Advisors LLC boosted its stake in shares of Novavax by 309.1% during the 2nd quarter. Worldquant Millennium Advisors LLC now owns 142,745 shares of the biopharmaceutical company's stock worth $7,341,000 after purchasing an additional 107,853 shares during the last quarter. Finally, Centiva Capital LP boosted its stake in shares of Novavax by 1,201.1% during the 2nd quarter. Centiva Capital LP now owns 103,397 shares of the biopharmaceutical company's stock worth $5,317,000 after purchasing an additional 112,787 shares during the last quarter. 42.63% of the stock is owned by institutional investors and hedge funds.
几家对冲基金最近调整了对该公司的持股。B.莱利财富管理公司(B.Riley Wealth Management Inc.)在第二季度增持了Novavax股票22.0%。B.莱利财富管理公司(B.Riley Wealth Management Inc.)现在持有这家生物制药公司的5,044股股票,价值25.9万美元,该公司在上个季度又购买了909股。CapTrust Financial Advisors在第二季度将其在Novavax的持股增加了83.3%。CapTrust Financial Advisors现在拥有这家生物制药公司6,703股股票,价值345,000美元,此前在上个季度又购买了3,047股。ExodusPoint Capital Management LP在第二季度将其在Novavax的股份增加了212.8%。ExodusPoint Capital Management LP现在拥有这家生物制药公司21,296股股票,价值1,095,000美元,此前在上个季度又购买了14,487股。Worldquant Millennium Advisors LLC在第二季度将其在Novavax的持股增加了309.1%。Worldquant Millennium Advisors LLC现在拥有142,745股这家生物制药公司的股票,价值7,341,000美元,上个季度又购买了107,853股。最后,Centiva Capital LP在第二季度将其在Novavax的股份增加了1,201.1%。Centiva Capital LP现在拥有这家生物制药公司103,397股股票,价值5,317,000美元,此前在上个季度又购买了112,787股。42.63%的股票由机构投资者和对冲基金持有。
About Novavax
关于Novavax
(Get Rating)
(获取评级)
Novavax, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.
Novavax,Inc.是一家生物技术公司,专注于疫苗的发现、开发和商业化,以预防严重的传染病和满足卫生需求。该公司的候选疫苗包括冠状病毒候选疫苗NVX-CoV2373,它正在进行两项第三阶段试验、一项IIb阶段试验和一项I/II阶段试验;NanoFlu,一种处于第三阶段临床试验的季节性四价流感疫苗候选产品;以及ResVax,一种呼吸道合胞病毒(RSV)融合(F)蛋白质纳米颗粒疫苗候选产品。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Novavax (NVAX)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- 免费获取StockNews.com关于Novavax的研究报告(NVAX)
- 华尔街对Datadog的热情会带来巨大的收益吗?
- MarketBeat:回顾一周9/19-9/23
- 为什么特斯拉的股票保持弹性?
- 小盘股的裁员是楼市的晴雨表吗?
- 好市多盈利后价格疲软是买入的好时机吗?
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.
接受Novavax Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Novavax和相关公司的最新新闻和分析师评级的每日简要摘要。